This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Bajaj Healthcare Q2 FY26 PAT jumps 38% YoY at Rs 14.4 cr
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bajaj Healthcare reported Q2 FY26 revenue from operations of Rs 17,690 lakhs, up 19.6 percent from Rs 14,791 lakhs YoY. Profit after tax from continuing operations rose 37.6 percent to Rs 1,438 lakhs versus Rs 1,045 lakhs. Half year revenue grew 15 percent to Rs 34,153 lakhs and H1 PAT was up 14.8 percent at Rs 2,827 lakhs. Board approved unaudited results with an unmodified limited review by Walker Chandiok. NCLT approved acquisition of Genrx Pharma as wholly owned subsidiary. Basic EPS for the quarter stood at Rs 4.19 versus Rs 3.53 YoY.
Strong double digit PAT growth and higher EPS are positive for shareholders. Discontinued operations drag remains but smaller. Genrx deal to widen pharma footprint.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹175.9 Cr | ₹147.9 Cr | +18.9% |
| Operating profit | ₹17.58 Cr | ₹14.31 Cr | +22.9% |
| Profit after tax | ₹14.09 Cr | ₹11.11 Cr | +26.9% |
| EBITDA margin | 17.7% | 18.2% | −0.5 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.